Analysts Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Price Target at $39.50

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has received a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $39.50.

GMAB has been the subject of several analyst reports. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday. New Street Research set a $43.00 price objective on shares of Genmab A/S in a report on Wednesday, July 22nd. Truist Financial assumed coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, HC Wainwright increased their target price on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd.

Hedge Funds Weigh In On Genmab A/S

A number of large investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC grew its holdings in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares during the period. Osaic Holdings Inc. raised its stake in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares during the period. V Square Quantitative Management LLC acquired a new position in shares of Genmab A/S during the 1st quarter worth approximately $34,000. NewEdge Advisors LLC lifted its position in shares of Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after buying an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. lifted its position in shares of Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after buying an additional 780 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Up 1.9%

Genmab A/S stock opened at $31.94 on Wednesday. The firm has a market cap of $19.92 billion, a price-to-earnings ratio of 25.15, a price-to-earnings-growth ratio of 1.86 and a beta of 0.83. Genmab A/S has a 52 week low of $23.14 and a 52 week high of $35.43. The business’s 50-day moving average price is $27.98 and its 200 day moving average price is $27.96. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. As a group, sell-side analysts anticipate that Genmab A/S will post 1.17 earnings per share for the current year.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.